University of Sydney-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

    Gut, Vol. 73, Núm. 5, pp. 825-834

2023

  1. Predicting liver-related events in NAFLD: A predictive model

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 4, pp. 1240-1251

2022

  1. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

    Gut, Vol. 71, Núm. 2, pp. 382-390

2021

  1. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease

    EBioMedicine, Vol. 70

  2. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

    Advanced Science, Vol. 8, Núm. 11

2020

  1. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease

    PLoS ONE, Vol. 15, Núm. 12 December

2019

  1. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR

    Journal of Hepatology, Vol. 70, Núm. 3, pp. 494-500

2018

  1. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

    Gastroenterology, Vol. 155, Núm. 2, pp. 443-457.e17